Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00392756 · ClinicalTrials.gov registry record · Phase 1
Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 624
- Enrollment target
NCT00392756: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00392756 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 624 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (940% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00392756, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 624 participants
- Enrollment target
Study Summary
The purpose of the study is to examine how Kallmann syndrome (KS) and idiopathic hypogonadotropic hypogonadism (IHH) affect reproductive hormones. These disorders are caused by a defect in Gonadotropin Releasing Hormone (GnRH) secretion. GnRH is a hormone released by a small gland in the brain called the hypothalamus. When GnRH is released, it signals another gland in the brain, the pituitary, to secrete the reproductive hormones that influence sex hormone (testosterone, estrogen) levels and gamete (sperm, egg cell) production. This study involves a detailed evaluation and 24-48 hours stay at the hospital. In this study, males and females ages 16 and older with IHH have a detailed evaluation which involves an overnight study at the hospital. Some men (18 years and older) may continue on to receive treatment with pulsatile GnRH. This treatment replaces the hormone which is absent in IHH and results in normalized testosterone and typically is effective in developing fertility.
Interventions
- DRUG gonadotropin releasing hormone (GnRH)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 624 participants |
| Start Date | 1989-04 |
| Est. Completion | 2019-05-16 |
| Phase | Phase 1 |
What the finished NCT00392756 record still lists
NCT00392756 is an interventional study that assigns participants to a tested intervention. The registered 624 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (940% higher).
The record links to 0 conditions, and to 1 intervention - of which gonadotropin releasing hormone (GnRH) is the first listed.
NCT00392756 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00392756 about?
NCT00392756 is a clinical study titled "Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)". The purpose of the study is to examine how Kallmann syndrome (KS) and idiopathic hypogonadotropic hypogonadism (IHH) affect reproductive hormones. These disorders are caused by a defect in Gonadotropin Releasing Hormone (GnRH) secretion. GnRH is a hormone released by a small gland in the brain calle...
What is the current status of trial NCT00392756?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 624 participants. The study started on 1989-04. Estimated completion is 2019-05-16.
What interventions are being tested in trial NCT00392756?
The interventions under investigation include: gonadotropin releasing hormone (GnRH) (DRUG).
Who is sponsoring clinical trial NCT00392756?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00392756's enrollment target sits among peer trials
624 23rd of 2000 higher than 1,978 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06406049 · 624 participants · NA
Finishing HIV Project
- NCT05349227 · 625 participants · NA
Comprehensive Outcomes for After Cancer Health
- NCT06103864 · 625 participants · Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- NCT06230510 · 625 participants · NA
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia